Clinuvel Pharmaceuticals Ltd
F:UR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
F:UR9
|
AU |
|
P
|
Pacific Biosciences of California Inc
F:P09
|
US |
|
C
|
China Eastern Airlines Corp Ltd
F:CIAH
|
CN |
|
C
|
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
|
AU |
|
M
|
MFEC PCL
SET:MFEC
|
TH |
Intrinsic Value
Is UR9 undervalued or overvalued?
See the intrinsic value estimate for 
Clinuvel Pharmaceuticals Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
UR9 looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with UR9’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Clinuvel Pharmaceuticals Does
Clinuvel Pharmaceuticals is a specialty drug company that makes treatments for rare skin and light-sensitivity disorders. Its best-known product is SCENESSE, a prescription medicine used to help people with erythropoietic protoporphyria, a condition that can make sunlight exposure painful and difficult to manage. The company also works on other therapies linked to skin protection and pigmentation.
- Headquarters
- Australia AU
- Employees
- 16
- IPO date
- Feb 13, 2001
Earnings Waterfall
Clinuvel Pharmaceuticals Ltd
The intrinsic value for Clinuvel Pharmaceuticals Ltd (UR9) under the Base Case is hidden EUR.
Compared with the current market price of 4.48 EUR, the stock appears hidden.